DEnosumab for the Treatment of FIbrous Dysplasia/McCune-Albright Syndrome in Adults (DeFiD)
Condition(s):Fibrous Dysplasia; McCune Albright SyndromeLast Updated:July 28, 2023Recruiting
Include Studies Not Open or Pending
Condition(s):Fibrous Dysplasia; McCune Albright SyndromeLast Updated:July 28, 2023Recruiting
Condition(s):Denosumab AllergyLast Updated:February 21, 2023Recruiting
Condition(s):Osteoporosis, PostmenopausalLast Updated:October 13, 2023Recruiting
Condition(s):Osteoporosis; Bone Mineral DensityLast Updated:October 25, 2021Recruiting
Condition(s):Denosumab vs ZoledronateLast Updated:February 21, 2023Recruiting
Condition(s):OsteoporosisLast Updated:March 26, 2024Not yet recruiting
Condition(s):Sarcopenia; Osteoporosis; DenosumabLast Updated:January 12, 2024Not yet recruiting
Condition(s):Chronic Kidney Diseases; Fracture; Bone Density, Low; End Stage Renal DiseaseLast Updated:January 25, 2023Recruiting
Condition(s):Multiple Myeloma; Bone DiseasesLast Updated:March 18, 2024Not yet recruiting
Condition(s):Osteopenia; Lumbar SpondylolisthesisLast Updated:February 21, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.